Efforts have been made to promote the coordinated development of various business segments in the whole industrial chain, while actions to deepen reform and improvement have been implemented,  accumulating strength for a new round of high-quality development.

The national layout strategy for the whole TCM healthcare industry chain has been determined, embracing rapid grow in scale and revenue. In 2017, the first revenue target of RMB 10 billion had been achieved. In 2021, the revenue exceed RMB20 billion, and the total profit exceed RMB2.5 billion, reaching a phased peak.

China TCM invested RMB 8.76 billion to acquire 87.3% shares in Jiangyin Tianjiang (and its wholly-owned subsidiary Yifang Pharmaceutical), being the largest M&A in the domestic pharmaceutical industry, establishing its leading position in the concentrated TCM granules industry, and further consolidating the industrial system structure, achieving the strategic transformation from focusing on TCM trade to industrial manufacturing.

Sino TCM turned to an enterprise with TCM finished drugs manufacturing as the main business, through M&A of Winteam Pharhmacetical (570.HK, then renamed as China TCM), and basically completed the construction of the business architecture and industrial base.

Sino TCM determined the strategy of transforming from TCM trade to TCM industry. 

China Medicinal Materials Company was established, and has successively established medicinal materials stations across the country, responsible for the comprehensive balance and industry management of the production, supply, and marketing of Chinese medicine across the country, for the inheritance and development of Chinese medicine in New China Make an indelible historical contribution.

China Medicinal Materials Company was merged into Sinopharm Group and became a wholly-owned subsidiary of Sinopharm Group, and then renamed as China Traditional Medicine Company and China Traditional Medicine Co., Ltd. (Sino TCM), establishing TCM segment platform for Sinopharm Group.